Compare OC & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OC | KRYS |
|---|---|---|
| Founded | 1938 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 7.8B |
| IPO Year | 2006 | 2017 |
| Metric | OC | KRYS |
|---|---|---|
| Price | $99.68 | $250.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | $153.00 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 1.5M | 207.9K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.06% | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | N/A | ★ 6.84 |
| Revenue | N/A | ★ $389,130,000.00 |
| Revenue This Year | N/A | $40.88 |
| Revenue Next Year | $3.73 | $35.16 |
| P/E Ratio | ★ N/A | $37.64 |
| Revenue Growth | N/A | ★ 33.94 |
| 52 Week Low | $97.53 | $123.03 |
| 52 Week High | $159.42 | $298.30 |
| Indicator | OC | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 27.52 | 43.73 |
| Support Level | $97.53 | $233.64 |
| Resistance Level | $144.62 | $293.60 |
| Average True Range (ATR) | 4.00 | 9.49 |
| MACD | -0.81 | -0.51 |
| Stochastic Oscillator | 6.13 | 30.30 |
Owens-Corning Inc is a building products company that offers roofing products and systems, insulation products (hermal and acoustical batts, loose fill insulation, spray foam insulation, wet use chopped strand, etc.), and doors and door systems. The company's reportable segments are: Roofing, Insulation, and Doors. Maximum revenue is generated from the Roofing segment, which manufactures and sells residential roofing shingles, oxidized asphalt materials, roofing components, and composite lumber mainly used in residential construction. This segment also manufactures and sells glass mat and specialty veil materials used in building and construction applications. Geographically, the company generates maximum revenue from the United States, followed by Europe, Asia-Pacific, and other markets.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.